Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.94 +7.9%	$3.20	$2.01 ▼ $5.64	$242.82M	1.52	1.21 million shs	2.12 million shs
NRIX Nurix Therapeutics	$12.21 -1.2%	$11.14	$8.18 ▼ $29.56	$942.27M	2.15	836,396 shs	565,267 shs
PHVS Pharvaris	$17.98 -0.1%	$17.07	$11.51 ▼ $25.50	$941.22M	-2.82	70,560 shs	13,793 shs
PRAX Praxis Precision Medicines	$46.76 +0.2%	$40.90	$26.70 ▼ $91.83	$950.82M	2.6	366,844 shs	395,323 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.16%	+15.87%	-5.93%	+43.14%	+65.16%
NRIX Nurix Therapeutics	-2.91%	+8.52%	-3.29%	+33.48%	-36.52%
PHVS Pharvaris	-4.05%	+2.27%	+7.27%	+52.16%	+8.11%
PRAX Praxis Precision Medicines	-1.26%	+11.01%	+4.76%	+63.22%	+15.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.6974 of 5 stars	3.4	1.0	2.6	0.0	0.6
NRIX Nurix Therapeutics	1.6045 of 5 stars	3.4	0.0	3.8	0.8	0.0
PHVS Pharvaris	1.773 of 5 stars	3.5	1.0	2.3	0.0	0.0
PRAX Praxis Precision Medicines	2.9433 of 5 stars	4.4	2.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	196.95% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	147.15% Upside
PHVS Pharvaris	3.00	Buy	$36.20	101.33% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$94.11	101.26% Upside

Current Analyst Ratings Breakdown

Latest CRDF, PHVS, NRIX, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	385.48	N/A	N/A	$1.86 per share	2.12
NRIX Nurix Therapeutics	$54.55M	17.06	N/A	N/A	$7.44 per share	1.64
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	111.40	N/A	N/A	$23.90 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)

Latest CRDF, PHVS, NRIX, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
NRIX Nurix Therapeutics	N/A	6.26	6.26
PHVS Pharvaris	N/A	11.10	11.10
PRAX Praxis Precision Medicines	N/A	8.44	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
NRIX Nurix Therapeutics	N/A
PHVS Pharvaris	N/A
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
NRIX Nurix Therapeutics	7.40%
PHVS Pharvaris	N/A
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable

CRDF, PHVS, NRIX, and PRAX Headlines

Recent News About These Companies

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $115.00 at Oppenheimer

July 8 at 1:39 PM | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule ...

July 2, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by Brokerages

June 28, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 51,682 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 14, 2025 | marketbeat.com

Needham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Former head trader of Denver-based investing company pleads guilty to insider trading

June 9, 2025 | finance.yahoo.com

Weston man pleads guilty to insider trading offense that made him $220K

June 8, 2025 | stamfordadvocate.comS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2025 | globenewswire.com

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 7, 2025 | benzinga.com

Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation

May 7, 2025 | msn.com

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

May 5, 2025 | finance.yahoo.com

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

May 4, 2025 | finance.yahoo.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

Praxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | Benzinga

April 21, 2025 | benzinga.com

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

April 8, 2025 | globenewswire.com

Praxis Precision Medicines to Participate in Upcoming April Conferences

April 3, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, PHVS, NRIX, and PRAX Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.94 +0.29 (+7.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 -0.02 (-0.38%)

As of 07:57 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Nurix Therapeutics NASDAQ:NRIX

$12.21 -0.15 (-1.21%)

As of 04:00 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Pharvaris NASDAQ:PHVS

$17.98 -0.02 (-0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$17.90 -0.08 (-0.44%)

As of 04:40 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Praxis Precision Medicines NASDAQ:PRAX

$46.76 +0.08 (+0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$46.76 0.00 (-0.01%)

As of 07:56 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time